Defining the Future of Pharmacometrics: The American Society of Pharmacometrics
Marc Pfister, Richard C. Brundage, Marc R. Gastonguay, Raymond Miller, Stacey J. Tannenbaum, David Z. D’Argenio · The Journal of Clinical Pharmacology · 2010
The contributions in this Special Issue of the Journal of Clinical Pharmacology reflect the dramatic evolution during the past 60 years of the field we now call pharmacometrics. A few of the pivotal organizational developments that have promoted the growth in the breadth and depth of activity in pharmacometrics are readily identifiable: Launch of the Journal of Pharmacokinetics and Biopharmaceutics in 1973 Introduction of a new section on pharmacometrics in Journal of Pharmacokinetics and Biopharmaceutics in 1982 Inaugural meeting of the Population Approach Group of Europe (PAGE) in 1992 Inaugural meeting of the American Conference on Pharmacometrics (ACoP) in 2008 As noted in the editorial preface to this supplement, Integration—Innovation—Impact can provide the thematic foundation for continued growth of the scientific discipline of pharmacometrics. To guide the continued revolutions around the Integration—Innovation—Impact circle of excellence, we are proposing the establishment of the American Society of Pharmacometrics (ASoP). An important part of the mission of ASoP is to serve as the sponsoring organization for the American Conference on Pharmacometrics. In addition, ASoP will actively (1) engage other pharmacometric communities in North America, Europe, Asia, and Australia/New Zealand as we strive to innovate and expand in pharmacometrics; (2) work to integrate national and international initiatives, consortia, and educational efforts involving pharmacometrics; and (3) collaborate with editors of existing journals to enhance the impact of pharmacometrics. The success and future growth of the American Society of Pharmacometrics require the continuous commitment, contributions and leadership of all of us who understand the central role pharmacometrics has in advancing innovative science and technology, and in optimizing discovery, development, and utilization of new medicines for the treatment and prevention of disease to improve human health and well-being. Financial disclosure: The articles in this supplement are sponsored by the American Conference on Pharmacometrics.